FXR Agonist M480, Exhibits Efficacy in Multiple Models of Inflammatory Bowel Disease (IBD) by Increasing Expression of Anti-Microbial Genes and Reducing Inflammatory Cytokine Expression in the Gut

Back
Poster presentation at DDW – Digestive Disease Week, May 2019

DDW 2019

Download PDF